证券代码：688130 证券简称：晶华微 公告编号：2023-044 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等相关规定，现将公司回购股份进展情况公告如下： 截至 2023 年 9 月 30 日，公司通过集中竞价交易方式已累计回购公司股份 369,168 股，占公司总股本 66,560,000 股的比例为 0.5546%，回购成交的最高价 为 43.64 元/股，最低价为 41.05 元/股，支付的资金总额为人民币 15,760,177.94 元（不含印花税、交易佣金等交易费用）。本次回购股份符合法律法规的规定及 公司的回购股份方案。 杭州晶华微电子股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至 2023 年 9 月 30 日，杭州晶华微电子股份有限公司（以下简称"公 司"）通过集中竞价交易方式已累计回购公司股份 369,168 股，占公司总股本 66,560,000 股的比例为 0.5546%，回购 ...

Group 1: Company Overview - The company is Hangzhou Jinghua Microelectronics Co., Ltd., with stock code 688130 and abbreviation Jinghua Micro [1] - The investor relations activity took place on September 22, 2023, in an offline meeting format [2] Group 2: Revenue Breakdown - In the first half of 2023, the revenue from medical health SoC chip products accounted for 57.46%, a year-on-year decrease of 13.33% [3] - Revenue from industrial control and instrumentation chip products represented 41.07%, showing a year-on-year increase of 10.83% [3] - Revenue from intelligent perception SoC chip products was 1.47%, with a significant year-on-year growth of 51.93% [3] Group 3: New Product Launches - In the first half of 2023, the company launched several new products, including high-performance pressure/temperature sensor signal conditioning chips and specialized SoC chips for blood pressure and blood glucose meters [3] - Upcoming products include high-performance eight-electrode body fat scale SoC chips and various other specialized chips, with several high-speed and high-resolution ADC chips expected to be mass-produced by the end of 2023 [3] Group 4: Competitive Advantages - The company's core technological advantages lie in its self-developed high-precision Sigma-Delta ADC SoC technology and low-power, high-interference resistance capabilities in industrial control chips, which are considered advanced domestically [4] - The company also emphasizes integrated solutions and rapid local response to customer feedback [4] Group 5: Client Relationships - Major clients for medical health SoC chips include Xiangshan Weighing Apparatus, Lexin Medical, and Wolai Technology; for industrial control and instrumentation chips, clients include Yuli De, Huashengchang, and Victory Instruments [4] - The company has been actively expanding its market presence and has made progress in collaborations with well-known brands in products like thermometers and uric acid meters [4] Group 6: R&D and Performance Goals - As of June 2023, the company had 124 R&D personnel, reflecting a year-on-year increase of 65.33% [4] - The company has launched a restricted stock incentive plan for 2023, aiming to increase market share and scale, with a target gross margin of 64.14% for the first half of 2023 [4]

证券代码：688130 证券简称：晶华微 公告编号：2023-043 一、回购股份的基本情况 2023 年 8 月 18 日，公司召开了第一届董事会第二十四次会议，审议通过了 《关于以集中竞价交易方式回购股份方案的议案》，同意公司使用超募资金通过 集中竞价交易方式回购公司已经发行的人民币普通股（A 股）股票，并在未来适 宜时机将前述回购股份用于员工持股计划或股权激励。本次回购的资金总额不低 于人民币 1,500 万元且不超过人民币 3,000 万元，回购的价格不超过人民币 60.00 元/股，回购期限自董事会审议通过回购股份方案之日起 12 个月内。具体内容详 见公司分别于 2023 年 8 月 19 日、2023 年 8 月 31 日在上海证券交易所网站 （www.sse.com.cn）披露的《关于以集中竞价交易方式回购股份方案的公告》（公 告编号：2023-035）和《关于以集中竞价交易方式回购公司股份的回购报告书》 （公告编号：2023-042）。 二、首次实施回购股份的情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等相关规定，现将公司首次回购股份情况公告如 ...

海通证券股份有限公司关于杭州晶华微电子股份有限公司 2023 年持续督导半年度跟踪报告 | 保荐机构名称：海通证券股份有限公司 | 被保荐公司简称：晶华微 | | --- | --- | | 保荐代表人姓名：薛阳、余冬 | 被保荐公司代码：688130 | 重大事项提示 2023 年 1-6 月，晶华微营业收入 6,493.21 万元，较上年同期下降 5.02%；归 属于上市公司股东的净利润为 221.88 万元，归属于上市公司股东的扣除非经常 性损益的净利润为-315.49 万元，分别较去年同期下降 91.53%、114.81%，下滑幅 度较大。公司预计未来在技术研发、人员费用方面仍需保持较大的投入。如果半 导体行业仍处于下行周期，消费景气度缓慢复苏，业务拓展及研发项目进展不及 预期，预计公司未来仍可能出现业绩下滑或亏损的情形。提醒广大投资者对公司 的业绩波动、由盈转亏的情况予以关注。 3 | 项 目 | 工作内容 | | --- | --- | | | 更正，并同步公告了更正后的定期报告；同 | | | 日，晶华微收到上海证券交易所出具的《关于 | | | 对杭州晶华微电子股份有限公司会计差错更 | | ...

标题：关于杭州晶华微电子股份有限公司会计差错更正事项的监管工作函 证券代码：688130 证券简称：晶华微 监管类型：监管工作函 涉及对象：上市公司,中介机构及其相关人员 处分日期：2023-08-30 处理事由：关于杭州晶华微电子股份有限公司会计差错更正事项的监管工作函 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥17,735,740.08, a decrease of 45.52% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2022 was ¥1,882,321.92, down 86.55% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥3,517,857.69, a decline of 125.42% compared to the previous year[5]. - Total operating revenue for the first three quarters of 2022 was CNY 86,097,759.42, a decrease from CNY 133,969,504.28 in the same period of 2021, representing a decline of approximately 35.8%[24]. - Net profit for the first three quarters of 2022 was CNY 28,063,290.03, compared to CNY 62,915,181.87 in 2021, reflecting a decrease of approximately 55.5%[25]. - The total comprehensive income for the third quarter of 2022 was CNY 28,063,290.03, a decrease from CNY 62,915,181.87 in the same period of 2021, representing a decline of approximately 55.5%[26]. - Basic and diluted earnings per share for the third quarter of 2022 were CNY 0.52, down from CNY 1.35 in the previous year, indicating a decrease of about 61.5%[26]. Research and Development - Research and development expenses totaled ¥12,950,712.10, an increase of 87.88% compared to the same period last year, representing 73.02% of operating revenue[6]. - Research and development expenses for the first three quarters of 2022 amounted to CNY 29,395,811.27, significantly higher than CNY 17,658,921.30 in the previous year, marking an increase of about 66.5%[24]. - The company plans to continue focusing on R&D and market expansion strategies to enhance future growth prospects[24]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,337,855,519.88, reflecting an increase of 248.70% from the end of the previous year[6]. - Total assets as of the end of the third quarter of 2022 were CNY 1,337,855,519.88, compared to CNY 383,671,323.60 at the same time in 2021, showing a substantial increase[23]. - Total liabilities for the third quarter of 2022 were CNY 22,779,105.13, up from CNY 20,583,832.52 in the previous year, indicating an increase of approximately 10.7%[22]. - The total equity attributable to shareholders was CNY 1,315,076,414.75, compared to CNY 363,087,491.08 in 2021, representing a significant growth[23]. Cash Flow - The cash flow from operating activities for the year-to-date was -¥16,077,406.01, a decline of 129.28%[6]. - Cash inflow from operating activities for the first three quarters of 2022 was CNY 122,073,454.24, compared to CNY 175,661,977.10 in the same period of 2021, reflecting a decline of approximately 30.5%[28]. - The net cash flow from operating activities for the first three quarters of 2022 was negative CNY 16,077,406.01, contrasting with a positive CNY 54,908,069.56 in the previous year[28]. - Cash inflow from investment activities for the first three quarters of 2022 was CNY 513,268,938.45, compared to CNY 430,200,019.15 in the same period of 2021, showing an increase of about 19.3%[28]. - The net cash flow from investment activities for the first three quarters of 2022 was negative CNY 236,653,445.48, an improvement from negative CNY 272,714,521.85 in the previous year[28]. - Cash inflow from financing activities for the first three quarters of 2022 was CNY 948,428,416.00, significantly higher than CNY 147,600,000.00 in the same period of 2021, indicating an increase of approximately 542.5%[29]. - The net cash flow from financing activities for the first three quarters of 2022 was CNY 918,386,890.10, compared to CNY 145,914,476.00 in the previous year, reflecting a substantial increase of about 528.5%[29]. - The ending balance of cash and cash equivalents as of the end of the third quarter of 2022 was CNY 941,294,899.39, a significant increase from CNY 2,778,212.34 at the end of the previous year[29]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,919[12]. - The company’s total number of shares held by the top 10 unrestricted shareholders includes significant holdings by major stakeholders, indicating strong insider confidence[14]. - The company has engaged in strategic placement plans for key employees and executives, enhancing alignment with shareholder interests[14]. Management Changes - The company’s financial director and board secretary resigned on September 30, 2022, with the chairman, Lü Huanquan, appointed to act in these roles temporarily[17]. Other Financial Metrics - The weighted average return on net assets decreased to 0.17%, down 3.93 percentage points year-on-year[6]. - The basic earnings per share for Q3 2022 was ¥0.03, a decrease of 89.29% compared to the same period last year[6]. - The company reported accounts receivable of ¥14,731,990.60 as of September 30, 2022, compared to ¥9,945,626.07 on December 31, 2021, indicating an increase of about 48%[20]. - The company has a total of 239,486,500.00 in trading financial assets as of September 30, 2022, with no previous data provided for comparison[20]. - The company’s prepayments decreased from ¥41,553,288.57 to ¥27,995,957.40, a decline of approximately 33%[20]. - The company has a total of 1,054,748.49 in notes receivable as of September 30, 2022, compared to ¥694,793.00 previously, marking an increase of about 52%[20]. - The company has a total of 389,402.17 in other receivables, up from ¥330,705.60, reflecting an increase of approximately 18%[20].

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, reaching RMB 500 million, representing a 25% year-over-year growth[14]. - The company's operating revenue for the first half of 2023 was ¥64,932,104.88, a decrease of 5.02% compared to the same period last year[19]. - The net profit attributable to shareholders was ¥2,218,788.96, down 91.53% year-on-year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥3,154,924.02, a decline of 114.81% compared to the previous year[19]. - The gross margin for the first half of 2023 improved to 45%, up from 40% in the same period last year[14]. - Basic and diluted earnings per share were both ¥0.03, down 94.23% from the same period last year[20]. - The company's net profit for the first half of 2023 was CNY 2,218,788.96, a decrease of 91.53% compared to CNY 26,180,968.11 in the same period of 2022[28]. - The company reported a total revenue of 18,910.00 million RMB for the first half of 2023, with a net profit of 3,019.93 million RMB, representing a significant increase from the previous year's 7,351.30 million RMB[60]. Research and Development - The company has invested RMB 50 million in R&D for innovative technologies, focusing on AI integration in its products[14]. - Research and development expenses reached ¥32,864,800, an increase of 99.85% year-on-year, with R&D expenses accounting for 50.61% of operating revenue, up 26.55 percentage points[22]. - The number of R&D personnel increased by 65.33% to 124 by the end of the reporting period[22]. - The company applied for 11 patents and obtained 3 during the reporting period, while it applied for 114 patents and obtained 87 in total[51]. - The company has developed a new calibration technology that significantly improves the performance of its DACs under varying temperature conditions[48]. - The company is actively recruiting high-end R&D talent to support its expansion into new fields[66]. Market Expansion and Strategy - The company is expanding its market presence, targeting new regions in Southeast Asia, aiming for a 10% market share by the end of 2024[14]. - The company has provided a positive outlook for the second half of 2023, projecting a revenue growth of 20% to 30%[14]. - New product launches are expected to contribute an additional 200 million RMB in revenue by the end of the year[130]. - The company is considering strategic acquisitions to bolster its market position, with potential targets identified in the tech sector[130]. - The company is focusing on expanding its market presence in the medical health sector, leveraging its advanced chip technology[35]. Product Development - New product development includes the launch of a next-generation chip expected to enhance performance by 40% over previous models, set to be released in Q4 2023[14]. - The company has developed a high-precision ADC-based signal processing SoC technology for medical health applications, including infrared temperature measurement chips[35]. - The company has developed a high-integration SoC chip for smart health scales, which eliminates the need for additional microcontrollers and display driver chips, providing a comprehensive single-chip solution for health monitoring[38]. - The company launched new products including high-performance blood pressure and blood glucose SoC chips, with Q2 revenue from temperature sensor chips increasing by 319.98% quarter-on-quarter[72]. Financial Management and Risks - The company faces risks related to market competition and reliance on a limited number of products, with over 95% of revenue coming from medical health and industrial control chips[79]. - The company has a risk of accounts receivable bad debts as its accounts receivable balance may increase with business expansion, which could adversely affect cash flow and operational performance if not collected in a timely manner[87]. - The company received a "High-tech Enterprise Certificate" valid for three years, allowing it to enjoy a 15% corporate income tax rate, but any changes to this tax policy could negatively impact future profitability[88]. - The company faces risks of technology and product obsolescence if competitors achieve breakthroughs in multi-chip combinations or if other companies with high-precision ADC technology enter its focus areas[92]. Shareholder Commitments and Governance - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of its IPO, ensuring stability in shareholding[125]. - The company will report any changes in shareholding through direct or indirect means, adhering to relevant laws and regulations[126]. - The company has established a compliance framework to ensure adherence to regulations regarding share transfers and holdings[128]. - The controlling shareholder and actual controller promise not to interfere in the company's management activities or infringe on the company's interests[136]. Environmental and Social Responsibility - The company promotes an environmental protection and hazardous substance management system throughout its supply chain[122]. - The company has committed to sustainability initiatives, aiming to reduce carbon emissions by 15% over the next three years[130]. - The company is not classified as a key pollutant discharge unit and does not engage in production activities that involve environmental pollution[122].

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 20%[16]. - The company reported a revenue of CNY 68.36 million for the first half of the year, a decrease of 32.59% compared to the same period last year[19]. - The company achieved operating revenue of 68.36 million yuan, a decrease of 32.59% year-on-year, and a net profit attributable to shareholders of 26.18 million yuan, down 46.48% year-on-year[68]. - The company reported a significant increase in revenue for the first half of 2022, with a year-on-year growth of 15%[133]. - The company provided guidance for the next quarter, expecting revenue to be between 1.6 billion and 1.8 billion, indicating a potential growth of 7% to 20%[124]. - The company reported a total comprehensive income of 27,367,739.25 RMB for the first half of 2022, contributing significantly to the increase in owner's equity[198]. Profitability and Margins - The gross profit margin improved to 35%, up from 30% in the same period last year, indicating better cost management and pricing strategies[16]. - The gross margin for the first half of the year was reported at 40%, consistent with the previous year[124]. - Net profit attributable to shareholders was CNY 26.18 million, down 46.48% year-on-year[19]. - The basic earnings per share decreased by 52.16% to CNY 0.52 from CNY 1.09 in the previous year[18]. - The company reported a significant decrease in net cash flow from financing activities, down 101.58% to -¥2,310,550.20, primarily due to the absence of capital contributions from shareholders compared to the previous year[98]. Research and Development - The company is investing RMB 50 million in R&D for new technologies, focusing on enhancing chip performance and energy efficiency[16]. - R&D expenses increased by 52.75% to CNY 16.44 million, representing 24.06% of revenue, an increase of 13.44 percentage points year-on-year[20]. - The company’s R&D investment reached 16,445,099.17 CNY, a 52.75% increase compared to the same period last year[51]. - The company has obtained 2 new invention patents, 1 utility model patent, and 6 software copyrights during the reporting period[49]. - The company is currently developing several projects, including a high-performance blood pressure and blood glucose meter SoC chip, with a total investment of 400,000 CNY[58]. Market Expansion and Strategy - Future outlook includes a revenue growth target of 25% for the full year 2022, driven by market expansion and new product launches[16]. - Market expansion efforts include entering two new international markets by the end of 2022, aiming for a 10% increase in overseas sales[16]. - The company plans to launch two new products in Q3 2022, which are expected to contribute an additional RMB 100 million in revenue[16]. - The company is considering strategic acquisitions to bolster its market position, with a budget of 100 million allocated for potential deals[124]. - The company is focused on expanding its market presence in the software and information technology services sector, particularly in integrated circuit solutions[200]. Operational Challenges and Risks - The management highlighted potential risks including supply chain disruptions and increased competition in the semiconductor industry[16]. - The company faced challenges due to logistics disruptions caused by the pandemic, impacting revenue and increasing R&D expenditures[19]. - The company operates under a Fabless model, leading to a high concentration of suppliers, which poses risks if any supplier faces disruptions[79]. - The company faces significant operational challenges due to tight capacity in wafer foundry and packaging testing, which may not meet procurement demands[80]. - The competitive landscape is intensifying, with numerous players entering the high-performance analog and mixed-signal IC market, posing challenges to the company's market position[78]. Shareholder and Governance Matters - The company committed to not transferring or entrusting shares held prior to the IPO for 12 months post-listing[125]. - The company will ensure compliance with relevant laws and regulations regarding shareholding and transfer[126]. - The company has established a profit distribution policy to ensure transparency and protect shareholder interests, with a focus on sustainable and stable returns[131]. - The company will report any changes in shareholding through direct or indirect means[126]. - The company has committed to compensating investors for any losses caused by false statements or omissions in its disclosure materials[132]. Assets and Liabilities - As of June 30, 2022, the company's total assets amounted to RMB 422,293,805.57, an increase from RMB 383,671,323.60 at the beginning of the period, reflecting a growth of approximately 10.4%[163]. - The company's total liabilities as of June 30, 2022, were RMB 30,788,995.53, up from RMB 20,583,832.52, indicating an increase of about 49.5%[165]. - Cash and cash equivalents decreased to RMB 134,378,697.84 from RMB 275,622,847.59, a decline of about 51.2%[163]. - Accounts receivable increased significantly to RMB 27,973,441.60 from RMB 9,945,626.07, marking a rise of approximately 181.5%[163]. - Inventory levels rose to RMB 65,829,848.12, up from RMB 45,779,377.87, reflecting an increase of around 43.8%[163].

证券代码：688130 证券简称：晶华微 公告编号：2023-041 杭州晶华微电子股份有限公司 关于前期会计差错更正及定期报告更正的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 杭州晶华微电子股份有限公司（以下简称"晶华微"或"公司"）于 2023 年 8 月 29 日召开第一届董事会第二十五次会议和第一届监事会第十七次会议，审议 通过《关于前期会计差错更正及定期报告更正的议案》。同意公司根据《公开发 行证券的公司信息披露编报规则第 19 号——财务信息的更正及相关披露》《企 业会计准则第 28 号——会计政策、会计估计变更和差错更正》等有关规定，对 公司于 2023 年 4 月 28 日披露了更正后的 2022 年半年度报告和 2022 年第三季度 报告进一步更正。现将相关情况公告如下： 一、 概述 （一）更正原因 公司将 2022 年期后退货作为资产负债表日后调整事项，相应调减了 2022 年度收入 1,738.07 万元。2022 年期后退货涉及的收入确认于 2022 年半年度，经 公司自查，上述销售发生时客户 ...

证券代码：688130 证券简称：晶华微 公告编号：2023-039 杭州晶华微电子股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集资金管理和 使用的监管要求》、《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 及《上海证券交易所科创板股票上市规则》等有关法律、法规及相关文件的规定，杭州晶华 微电子股份有限公司（以下简称"公司"）将 2023 年半年度募集资金存放与使用情况专项 说明如下： 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意杭州晶华微电子股份有限公司首次公开发行股 票注册的批复》（证监许可〔2022〕1203 号），本公司由主承销商海通证券股份有限公司 采用向战略投资者定向配售、网下向符合条件的网下投资者询价配售与网上向持有上海市场 非限售 A 股股份和非限售存托凭证市值的社会公众投资者定价发行相结合的方式发 ...